Oxurion continues discussions for the acquisition of a French CRO

Oxurion NV, a biopharmaceutical company based in Leuven, has extended negotiations for the acquisition of a majority stake in a French CRO by three months. This announcement follows Oxurion's commitment made on October 13, 2025. The purpose of the extension is to continue due diligence, which is essential for validating the target company's business plan.

Oxurion remains committed to keeping the market informed of the progress of this project. The company, listed on Euronext Brussels, specializes in acquiring stakes in promising European pharmaceutical subcontractors. It aims to integrate these entities to strengthen its services to healthcare stakeholders.